Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia

• Type of Material: Article
• Authors: H Jean Khoury, Emory University; C Gambacorti-Passerini, San Gerardo Hospital; TH Brümmendorf, University Hospital of the RWTH Aachen
• Language: English
• Date: 2018-03-01
• Publisher: Oxford University Press
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
• Final Published Version (URL): http://dx.doi.org/10.1093/annonc/mdy019
• Title of Journal or Parent Work: Annals of Oncology
• ISSN: 0923-7534
• Volume: 29
• Issue: 3
• Start Page: 578
• End Page: 587
• Grant/Funding Information: The phase I/II study (study 200; NCT00261846), for which previously unpublished data have been reported in the text and Tables ​Tables11 and ​and3,3, was sponsored by Pfizer (no grant number applies).; THB received research funding from Novartis; served as a consultant for Novartis, Ariad, Pfizer Inc, and Bristol-Myers Squibb; and holds a patent on the use of imatinib and hypusination inhibitors.
• Keywords: tyrosine kinase inhibitors; chronic myeloid leukemia; bosutinib; BCR-ABL1; safety
• Research Categories: Health Sciences, Oncology

Abstract

Bosutinib (SKI-606) is an oral, dual Src/Abl tyrosine kinase inhibitor (TKI) approved for treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that is resistant or intolerant to prior TKI therapy or for whom other TKIs are not appropriate choices. The objective of this review is to provide a longitudinal summary of toxicities that may arise during treatment with second-line or later bosutinib in patients with Ph+ chronic phase CML and to provide strategies for managing these toxicities. As bosutinib is not currently indicated for newly diagnosed CML, toxicities associated with first-line treatment are not reviewed. Recognition and optimal management of these toxicities can facilitate patient compliance and affect treatment outcomes.